Skip to main content
Revista Latino-Americana de Enfermagem logoLink to Revista Latino-Americana de Enfermagem
. 2018 Nov 29;26:e3085. doi: 10.1590/1518-8345.2774.3085

Prevalence of serological markers for hepatitis and potential associated factors in patients with diabetes mellitus

Clarissa Cordeiro Alves Arrelias 1, Fernando Belissimo Rodrigues 2, Maria Teresa da Costa Gonçalves Torquato 3, Carla Regina de Souza Teixeira 4, Flávia Fernanda Luchetti Rodrigues 4, Maria Lucia Zanetti 4
PMCID: PMC6280183  PMID: 30517576

ABSTRACT

Objective:

to estimate the prevalence of serological markers for hepatitis B and C in patients with diabetes mellitus and analyze potential associated factors.

Method:

a cross-sectional study with 255 patients with diabetes mellitus. Demographic, clinical, and risk behavior factors for hepatitis B and C were selected. The markers HBsAg, Anti-HBc IgG, Anti-HBc IgM, Anti-HBs, and Anti-HCV were investigated. A questionnaire and venous blood collection and inferential statistical analysis were used.

Results:

16.8% of the patients had a total reactive Anti-HBc marker, 8.2% an isolated Anti-HBs, and 75% were non-reactive for all hepatitis B markers. No case of reactive HBsAg was found and 3.3% of the patients had a reactive anti-HCV marker. The prevalence of prior hepatitis B virus infection was directly associated with the time of diabetes mellitus and the prevalence of hepatitis C virus infection was not associated with the investigated variables. The prevalence of hepatitis B and C infection in patients with diabetes mellitus was higher when compared to the national, with values of 16.8% and 3.3%, respectively.

Conclusion:

the results suggest that patients with diabetes are a population of higher vulnerability to hepatitis B and C, leading to the adoption of preventive measures of their occurrence.

Descriptors: Diabetes Mellitus, Hepatitis B, Hepatitis C, Immunization Coverage, Liver Diseases, Nursing

Introduction

The international literature shows outbreaks of hepatitis B virus (HBV) and hepatitis C virus (HCV) infection in the hospital, outpatient, and long-term care facilities. Infection cases have been shown to be more frequent in patients with diabetes mellitus (DM) than in those without the disease, suggesting that patients with DM are potentially more susceptible to HBV and HCV infection as a result of treatment and control procedures of the disease, in particular, the monitoring of capillary glycemia 1 - 8 .

These outbreaks occur when infection control standards during capillary glycemia monitoring are neglected, such as the sharing of lancet pens, lancets, and glucometers without the proper disinfection process due to the transmission of microorganisms through the blood. HBV and HCV can survive on surfaces such as lancet pens, lancets, and glucometers on average for five to seven days, even in the absence of visible blood. During this period, the virus can cause infection if it reaches the bloodstream of a susceptible person 9 - 10 .

There is evidence that the severity and lethality related to HBV and HCV infection are higher in patients with DM than in those without the disease. Studies show that in patients infected with HBV and HCV, the presence of DM can accelerate the progression of liver disease, lead to cirrhosis, hepatocellular carcinoma, and death 11 - 12 . In addition, HBV and HCV infection may negatively influence the glycemic control of patients with DM, increasing the risk of hyperglycemia 13 - 15 .

However, in Brazil, there is a shortage of studies regarding the behavior of hepatitis B and C in patients with DM. Regarding hepatitis C, four studies were identified in patients with DM 16 - 18 . One of them showed a high prevalence of hepatitis C in patients with type 2 diabetes mellitus (DM2) when compared to blood donors without DM 16 . Another study also found a high prevalence of hepatitis C in patients with DM2 18 . On the other hand, studies did not identify a difference in the prevalence of hepatitis C in patients with and without DM 14 and cases of hepatitis C in investigated patients with DM2 17 .

A study on the occurrence of hepatitis showed the magnitude of the prevalence of Hepatitis A, B, and C Virus Infections in the Brazilian macro-regions and represented a major step in coping with hepatitis in Brazil 19 . However, the behavior of the disease in individuals with DM and risk factors related to infection in this population is unknown.

Thus, considering the significant increase in the prevalence of DM in the city of Ribeirão Preto, SP, Brazil, from 12.1% in 1997 to 15.1% in 2006, the impact of HBV and HCV infection on morbidity and mortality, aggravated by DM, that patients with DM constitute an increased risk population for hepatitis B and C, this study aimed to estimate the prevalence of serological markers for hepatitis B and C in patients with DM and analyze potential related risk factors. We believe that the proposed study can provide subsidies to know the magnitude of the problem and to advance the production of knowledge about hepatitis B and C and DM. This study may represent the emergence of a new research topic that could lead to other studies, translating into the quality of health information and, therefore, an improvement in the healthcare network.

Method

This is a cross-sectional study carried out in a secondary health unit in of a city in the State of São Paulo, Brazil. The study population consisted of 314 patients with type 1 and 2 DM, who attended at least one consultation in the period from July to December 2014. All patients of both sexes, aged 18 years or more, with a diagnosis of type 1 and 2 DM registered in the health records, and who attended the medical consultation from July to December 2014 were considered as eligible. Seven patients were excluded due to hearing or cognitive limitations that made it impossible to answer the questions of the instrument, and other 17 due to the difficulty of establishing contact by the researcher. Thus, 290 patients with DM were invited to participate in the study, of whom 35 refused. The main reasons cited for the refusal were the lack of time to answer the questionnaire, lack of interest in participating in the study because they had already participated in other research projects, and unavailability for blood collection. The convenience sample consisted of 255 patients with DM who attended the medical consultation during the data collection period and met the inclusion criteria. This value (n=255) represents 88% of the patients invited to participate in the study, 81% of the study population and 39% of the patients with DM attended in that unit in 2014. The explanatory variables were demographic (sex, age, and schooling) and clinical (DM time, insulin use, capillary glycemia monitoring, medical, surgical, diagnostic, and therapeutic interventions, behaviors and situations of risk for hepatitis B and C), and the outcomes were HBV and HCV infection.

For this study, the researcher elaborated the questionnaire Occurrence of Serological Markers for Hepatitis B and C in Patients with Diabetes Mellitus based on the questionnaire for adolescents and adults used in the National Survey of Prevalence of Hepatitis A, B and C Virus Infections 20 , the researcher’s experience with patients with DM, and an extensive literature review on the subject 7 - 8 , 19 - 23 . The questionnaire was composed of 96 questions subdivided into five parts: Identification (11 questions); Demographic variables (four questions); Clinical variables (51 questions); Behavioral variables (24 questions); and Results of serology tests for hepatitis B and C (six questions).

The data collection instrument was pre-tested with ten patients in order to identify possible adjustments in the sequence of questions, test the approach to the patient, as well as estimate the time of application of the questionnaire. For data collection, the researcher had the collaboration of a student of Scientific Initiation previously qualified in order to standardize it. After the application of the pre-test, the questionnaire was maintained with no need for adjustments regarding its form and content. The ten patients were included in the final study sample. The data collection was carried out from July to December 2014.

Among the 255 patients, 226 attended the unit to collect blood, 19 performed the collection at home, and 10 patients refused to collect blood. Thus, 245 patients performed blood collection. The main reasons for the refusal were the lack of time and the withdrawal from participation in this phase of data collection.

The statistical analysis of the data was performed using the program STATA 11.0 (StataCorp LP, College Station, USA). The description of demographic and clinical data was presented through descriptive statistics, considering all the patients who participated in the study (n=255). The serological analysis for hepatitis B in patients who underwent blood sampling (n=245) enabled to evaluate the presence of the markers HBsAg, Anti-HBc IgG, Anti-HBc IgM, e Anti-HBs. Because the markers HBsAg and Anti-HBc IgM were non-reactive for all patients for analysis and data presentation, the marker total Anti-HBc was considered as equivalent to Anti-HBc IgG. The serological analysis for hepatitis C allowed evaluating the presence of the marker Anti-HCV. A reactive result for this marker was considered an HCV infection. The univariate analysis of possible associations between demographic and clinical variables and HBV and HCV infection was determined by the Pearson-corrected chi-square test or two-tailed Fisher exact test and Wilcoxon test. The project was approved by the Research Ethics Committee under No. CAAE 24638213.2.0000.5393.

Results

The demographic and clinical characteristics of the 255 (100%) investigated patients are described in Table 1.

Table 1. Distribution of patients with DM* according to demographic and clinical variables. Ribeirão Preto, SP, Brazil, 2014.

Demographic variables n %
Gender
Male 85 33.3
Female 170 66.7
Age
Median (p25-p75) 63 (55-71)
Schooling
Illiterate 9 3.5
Adult literacy 2 0.8
Incomplete 1st to 4th grade of Elementary School 51 20.0
Complete 1st to 4th grade of Elementary School 69 27.1
Incomplete 5th to 8th grade of Elementary School 26 10.2
Complete 5th to 8th grade of Elementary School 31 12.2
Incomplete High School 8 3.1
Complete High School 39 15.3
Incomplete Higher Education 10 3.9
Complete Higher Education 10 3.9
Time of DM* (years)
Median (p25-p75) 10 (4-20)
Use de insulin
No 105 41.2
Yes 150 58.8
Monitoring of capillary glycemia
No 65 25.5
Yes 190 74.5

*DM - Diabetes mellitus

Among the 245 (100%) patients who attended the blood collection, 41 (16.8%) presented a marker corresponding to prior infection with a spontaneous cure, 20 (8.2%) presented vaccination seroconversion and, 184 (75%) presented susceptibility to infection. No cases of acute or chronic hepatitis B were found. Therefore, the prevalence of prior HBV infection found in patients with DM was 16.8%.

Table 2 shows the results obtained from the univariate analysis of prior HBV infection according to demographic and clinical variables. The prior infection had a direct association with age (p=0.014) and DM time (p=0.043). No significant association was observed for the other variables.

Table 2. Distribution of patients with DM* with and without prior hepatitis B according to demographic and clinical variables of DM*. Ribeirão Preto, SP, Brazil, 2014.

Variables Total Anti-HBc p
(-) (+)
n % n %
Total 204 83.2 41 16.8
Gender
Male 63 30.9 17 41.5
Female 141 69.1 24 58.5 0.187
Age
Median (p25-p75) 62.8 (55.2-69.3) 68.4 (58.9-75.2) 0.014§
Schooling
Illiterate 6 2.9 3 7.3
Adult literacy 1 0.5 1 2.4
Incomplete 1st to 4th grade of Elementary School 40 19.6 9 22.0
Complete 1st to 4th grade of Elementary School 57 28.0 8 19.5
Incomplete 5th to 8th grade of Elementary School 19 9.3 6 14.6
Complete 5th to 8th grade of Elementary School 25 12.3 4 9.8
Incomplete High School 8 3.9 - -
Complete High School 31 15.2 7 17.1
Incomplete Higher Education 8 3.9 2 4.9
Complete Higher Education 9 4.4 1 2.4 0.521II
Time of DM* (years)
Median (p25-p75) 10 (4-19) 12 (10-23) 0.043II
Use of insulin
No 82 40.2 19 46.3
Yes 122 59.8 22 53.7 0.466
Monitoring of capillary glycemia
No 51 25.0 10 24.4
Yes 153 75.0 31 75.6 0.934

*DM - Diabetes mellitus; †Anti-HBc - Antibody (IgM or IgG) against hepatitis B virus core antigen; ‡Pearson-corrected chi-square test; §Wilcoxon test; ||Two-tailed Fisher exact test

Table 3 shows the univariate analysis of prior infection according to variables related to the history of medical, surgical, diagnostic, and therapeutic interventions and situations and behaviors of risk for hepatitis B. The results show an association between prior infection and report of home contact with case of hepatitis B (p=0.001), work as a police officer (p=0.016), and higher number of sexual partners throughout life (p=0.004).

Table 3. Distribution of patients with DM* with and without prior hepatitis B according to the history of medical, surgical, diagnostic, and therapeutic interventions and situations and behaviors of risk for hepatitis B. Ribeirão Preto, SP, Brazil, 2014.

Variables Total Anti-HBc p
(-) (+)
n % n %
Total 204 83.2 41 16.8
History of interventions
Hospitalization 132 64.7 27 65.8 0.888§
Surgery 161 16.3 33 80.5 0.822§
Blood/derivative transfusion 40 19.6 4 9.8 0.181II
Dental treatment 162 79.4 29 70.7 0.221§
Endoscopy 75 36.8 14 34.2 0.750§
Hemodialysis 3 1.5 - - 1.000II
Situations and behaviors of risk
Home contact with case of hepatitis B 3 1.5 6 14.6 0.001II
Sexual contact with case of hepatitis B 1 0.5 - - 1.000II
Sharing of sharps 84 41.2 13 31.7 0.258II
Tattoo 8 3.9 1 2.4 1.000II
Piercing 4 2.0 - - 1.000II
Health professional 19 9.3 4 9.8 1.000II
Work as a police officer 1 0.5 3 7.3 0.016
Work as a penitentiary agent/prison officer 1 0.5 - - 1.000II
Worker collecting household/hospital waste 7 3.4 1 2.4 1.000II
Work as a manicurist/chiropodist/podiatrist 11 5.4 1 2.4 0.696II
Smoked drugs 3 1.5 1 2.4 0.522II
Smelled drugs 2 1.0 1 2.4 0.424II
Condom use 16 7.8 2 4.9 1.000II
Sexually transmitted disease 30 14.7 8 19.5 0.438II
Number of sexual partners throughout life Median (p25-p75) 1 (1-3.5) 3 (1-10) 0.004
Frequency of alcohol consumption (last three months)
None 153 75.0 29 70.7
Once a month 19 9.3 4 9.8
Two to three times a month 15 7.4 3 7.3
One to two days a week 13 6.4 2 4.9
Three to four days a week 1 0.5 3 7.3
Almost everyday 2 1.0 - -
Every day 1 0.5 - - 0.202

*DM - Diabetes mellitus; †Anti-HBc - Antibody (IgM or IgG) against hepatitis B virus core antigen; ‡Non-mutually exclusive categories; §Pearson-corrected chi-square test; ||Two-tailed Fisher exact test; ¶Wilcoxon test

The explanatory variables included in the logistic regression analysis were those that showed a possible association with the outcome (p≤0.20). Among the variables included in the model, disease duration remained directly associated with the prior infection after the multivariate analysis, in which the DM time increases the risk of hepatitis B in approximately 4% each year of diagnosis of the disease. In addition, the work as a police officer was associated with infection (Table 4).

Table 4. − Logistic regression model for prior hepatitis B. Ribeirão Preto, SP, Brazil, 2014.

Variables* OR (95% CI) p Standard error
Female 0.74 (0.32-1.71) 0.487 0.31
Age 1.02 (0.99-1.06) 0.143 0.01
Time of DM§ 1.04 (1.00-1.08) 0.024 0.01
Home contact hepatitis B 0.97 (0.85-1.10) 0.658 0.06
Work as a police officer 13.82 (1.27-149.94) 0.031 16.81
Sexual partners throughout life 1.00 (0.99-1.00) 0.927 0.001
Alcohol consumption 1.04 (0.75-1.44) 0.806 0.17
Blood/derivative transfusion 0.55 (0.17-1.72) 0.309 0.32

*Those that showed p≤0.20 in the univariate analysis were included. Each variable was adjusted for the other seven; †OR - Odds ratio; ‡CI - Confidence interval; §DM - Diabetes mellitus

Among the 245 investigated patients, 8 (3.3%) presented a reactive anti-HCV marker. Therefore, the prevalence of HCV infection found in patients with DM was 3.3%. No significant association was found between the investigated demographic and clinical variables and HCV infection.

Discussion

When comparing the obtained results with the population-based survey conducted in Brazil, the prevalence of HBV exposure (16.8%) was higher than the national prevalence (11.6%) in the general population from 20 to 69 years. Regarding the prevalence of acute or chronic infection, the prevalence found was lower than the national prevalence, with a value of 0.6% 19 . This result suggests that the prevalence of HBV exposure is higher in individuals with DM when compared to those without the disease 5 .

The prevalence of prior cured infection and vaccine immunity marker were higher than in Spain 24 . On the other hand, studies carried out in Poland and Turkey showed two-fold higher values 25 - 27 . Other studies also found a higher prevalence 16 , 25 - 29 .

The association of exposure to HBV and a longer time of DM can be interpreted as a cumulative risk of exposure to the virus probably attributed to the disease management since DM does not progress to hepatitis B or C. The association of exposure to HBV and a longer time of DM were reported in Poland 26 , Turkey 28 , and Nigeria 30 . On the other hand, a study carried out in Italy found no association of infection and time of DM 27 .

In accordance with another study 27 , the present study also did not find an association of HBV infection with demographic variables, variables related to insulin use, monitoring of capillary glycemia, and history of medical, surgical, diagnostic, and therapeutic interventions. In addition, the majority of the investigated patients monitored capillary glycemia at home and outbreaks of HBV infection reported in the literature were in institutionalized patients and health services undergoing assisted monitoring of capillary glycemia without proper infection control practices 1 - 2 , 4 , 6 .

The prevalence of HCV infection was 3.3% higher than the national prevalence for the general population from 20 to 69 years old, which was 1.6% 24 , 27 , as well as national studies with specific populations such as the deaf, military males, and workers collecting household waste 31 - 33 . On the other hand, a study that investigated the prevalence of HCV infection in elderly patients in southern Brazil found a prevalence of 2.2% 34 .

The prevalence of hepatitis C in patients investigated in our study was also higher than that found in three national studies with patients with DM 16 - 17 . The difference in the observed prevalence can be attributed to the composition of the sample regarding the age group. An old age is considered a risk factor for exposure to HCV infection 20 - 21 . The time of DM found in these studies was also lower than that found in our study, which may also justify the difference in the observed prevalence.

On the other hand, a study carried out in southern Brazil showed that the prevalence was four times higher in patients with DM2 undergoing outpatient care 18 . The time of DM of the investigated outpatients is higher when compared to those of our study, which may have contributed to a higher prevalence of infection.

International studies investigating the prevalence of HCV exposure in patients with DM in an outpatient clinic or hospital found a lower 7 , 24 , 30 , similar 23 , 28 , and higher 8 , 22 , 25 , 27 , 29 prevalence in relation to our results.

Since the 1990s studies have shown a higher prevalence of hepatitis C in patients with DM when compared to those without this disease 7 - 8 , 16 , 23 , 27 . When comparing the prevalence of hepatitis C in patients with DM found in our study (3.3%) and the prevalence observed in the general Brazilian population (1.4%) 19 , we also observed a higher prevalence of infection in patients with DM.

However, in our study, although we found a prevalence of HCV infection higher than that of the Brazilian population, we did not observe an association of HCV infection with demographic variables, variables related to insulin use, monitoring of capillary glycemia, and history of medical, surgical, diagnostic, and therapeutic interventions, which is in agreement with national studies 16 - 18 .

Other studies reported in the international literature found as variables associated with infection only recognized risk factors for hepatitis C such as the history of blood transfusion, sharing of sharps, multiple sexual partners, and changes in liver enzyme levels 16 , 18 , 23 , 25 , 29 .

A study carried out in France found a significant difference in the prevalence of HCV infection in patients with (3.1%) and without DM (0.04%). However, the hypothesis that the type of treatment for DM, previous hospitalizations, and lancet use pen for monitoring the capillary glycemia are associated with HCV infection in patients with DM has not been confirmed 35 .

These results lead to the assumption that HCV infection may present as a risk factor for the development of DM, as investigated in other studies 36 - 37 . Studies have shown that HCV infection is followed by defects in the insulin-signaling pathway in the liver, which may contribute to insulin resistance and DM 37 . However, HCV-induced insulin resistance mechanisms are still partially understood 14 , 38 . Another study shows that liver inflammation is a possible risk factor for pre-diabetes in the context of HCV infection 39 .

In summary, when considering the higher prevalence of HBV exposure and its relation to the time of DM, it is suggested to deepen new investigations related to diabetes management that may contribute to HBV infection. The absence of association of HCV infection with the studied variables can be attributed to the relatively low number of infected individuals. This research is a pioneer in Brazil and offers subsidies for comparisons with future studies and advances in the knowledge of the subject.

This study offers subsidies to know the magnitude of the problem and advance the production of knowledge about hepatitis B and C and DM. The study can generate new research themes, translating into the quality of health information and, therefore, qualification of nursing care.

Conclusion

The prevalence of HBV infection in patients with DM was 16.8%, which is higher than the national level and was directly associated with the time of DM. No cases of acute or chronic hepatitis B were found. The prevalence of HCV infection was 3.3%, which is higher than the national level and had no association with the investigated demographic and clinical variables. Further studies need to be developed to investigate these issues and deepen the knowledge of the relationship between hepatitis C and DM in the national population aiming at the timely adoption of preventive measures.

Footnotes

*

Paper extracted from doctoral dissertation, “Prevalence of serological markers for hepatitis B and C and potential risk factors in patients with diabetes mellitus at a Basic Health District Unit”, presented to Escola de Enfermagem de Ribeirão Preto, Universidade de São Paulo, PAHO/WHO Collaborating Centre for Nursing Research Development, Ribeirão Preto, SP, Brazil.

References

  • 1.Bender TJ, Wise ME, Utah O, Moorman AC, Sharapov U, Drobeniuc J. Outbreak of hepatitis B virus infections associated with assisted monitoring of blood glucose in an assisted living facility-Virginia, 2010. PLoS One. 2012;7(12):e50012. doi: 10.1371/journal.pone.0050012. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Lanini S, Garbuglia AR, Puro V, Solmone M, Martini L, Arcese W. Hospital cluster of HBV infection Molecular evidence of patient-to-patient transmission through lancing device. PLoS One. 2012;7(3):e33122. doi: 10.1371/journal.pone.0033122. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Reilly ML, Schillie SF, Smith E, Poissant T, Vonderwahl CW, Gerard K. Increased Risk of Acute Hepatitis B among Adults with Diagnosed Diabetes Mellitus. J Diabetes Sci Technol. 2012;6(4):858–866. doi: 10.1177/193229681200600417. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Schaffzin JK, Southwick KL, Clement EJ, Konings F, Ganova-Raeva L, Xia G. Transmission of hepatitis B virus associated with assisted monitoring of blood glucose at an assisted living facility in New York State. Am J Infect Control. 2012;40(8):726–731. doi: 10.1016/j.ajic.2011.11.002. [DOI] [PubMed] [Google Scholar]
  • 5.Schillie SF, Xing J, Murphy TV, Hu DJ. Prevalence of hepatitis B virus infection among persons with diagnosed diabetes mellitus in the United States, 1999-2010. J Viral Hepatol. 2012;19(9):674–676. doi: 10.1111/j.1365-2893.2012.01616. [DOI] [PubMed] [Google Scholar]
  • 6.Diercke M, Monazahian M, Petermann H, Gerlich WH, Schüttler CG, Wend U. Hepatitis B outbreak in a nursing home associated with reusable lancet devices for blood glucose monitoring, Northern Germany 2010. J Med Virol. 2015;87(4):583–588. doi: 10.1002/jmv.24104. [DOI] [PubMed] [Google Scholar]
  • 7.Ba-Essa EM, Mobarak EI, Al-Daghri NM. Hepatitis C virus infection among patients with diabetes mellitus in Dammam, Saudi Arabia. BMC Health Serv Res. 2016;16:313–313. doi: 10.1186/s12913-016-1578-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Kanwal N, Nasir B, Abrar MA, Kaukab I, Nawaz A, Nisar N, et al. Prevalence of hepatitis C in diabetic patients: a prospective study. Acta Pol Pharm. 2016;73(3):771–775. https://www.ncbi.nlm.nih.gov/pubmed/27476296 [PubMed] [Google Scholar]
  • 9.Bond WW, Favero MS, Petersen NJ, Gravelle CR, Ebert JW, Maynard JE. Survival of hepatitis B virus after drying and storage for one week. Lancet. 1981;1(8219):550–551. doi: 10.1016/S0140-6736(81)92877-4. [DOI] [PubMed] [Google Scholar]
  • 10.Doerrbecker J, Friesland M, Ciesek S, Erichsen TJ, Mateu-Gelabert P, Steinmann J. Inactivation and survival of hepatitis C virus in inanimate surfaces. J Infect Dis. 2011;204(12):1830–1838. doi: 10.1093/infdis/jir535. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Huang YW, Wang TC, Lin SC, Chang HY, Chen DS, Hu JT. Increased risk of cirrhosis and its decompensation in chronic hepatitis B patients with new onset diabetes a nationwide cohort study. Clin Infect Dis. 2013;57(12):1695–1702. doi: 10.1093/cid/cit603. [DOI] [PubMed] [Google Scholar]
  • 12.Doerrbecker J, Friesland M, Ciesek S, Erichsen TJ, Mateu-Gelabert P, Steinmann J. Type 2 diabetes a risk factor for liver mortality and complications in hepatitis B cirrhosis patients. J Infect Dis. 2011;204(12):1830–1838. doi: 10.1093/infdis/jir535. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Lecube A, Hernández C, Genescà J, Simó R. Glucose abnormalities in patients with hepatitis C virus infection epidemiology and pathogenesis. Diabetes Care. 2006;29(5):1140–1149. doi: 10.2337/diacare.2951140. [DOI] [PubMed] [Google Scholar]
  • 14.Gutiérrez-Grobe Y, Ponciano-Rodríguez G, Méndez-Sánchez N. Viral hepatitis infection and insulin resistance: a review of the pathophysiological mechanisms. Salud Publica Mex. 2011;53:S46–S51. https://www.ncbi.nlm.nih.gov/pubmed/21877073 [PubMed] [Google Scholar]
  • 15.Gundling F, Seid H, Strassen I, Haller B, Siegmund T, Umgelter A. Clinical manifestations and treatment options in patients with cirrhosis and diabetes mellitus. Digestion. 2013;87(2):75–84. doi: 10.1159/000343458. [DOI] [PubMed] [Google Scholar]
  • 16.Parolin MB, Réa R, Vargas RM, Almeida ACR, Baldanzi GR, Lopes RW. Prevalence of hepatitis C infection in patients with type 2 diabetes mellitus Arq. Gastroenterol. 2006;43(2):77–80. doi: 10.1590/S0004-28032006000200003. [DOI] [PubMed] [Google Scholar]
  • 17.Costa LMFC, Mussi ADH, Brianeze MR, Souto FJD. Hepatitis C as a risk factor for diabetes type 2 lack of evidence in a hospital in central-west Brazil. Braz J Infect Dis. 2008;12(1):24–26. doi: 10.1590/S1413-86702008000100007. [DOI] [PubMed] [Google Scholar]
  • 18.Greca LF, Pinto LC, Rados DR, Canani LH, Gross JL. Clinical features of patients with type 2 diabetes mellitus and hepatitis C infection. Braz J Med Biol Res. 2012;45(3):284–290. doi: 10.1590/S0100-879X2012007500013. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Pereira LM, Martelli CM, Merchán-Hamann E, Montarroyos UR, Braga MC, Lima ML, et al. Population-Based Multicentric Survey of Hepatitis B Infection and Risk Factor Differences among Three Regions in Brazil. Am J Trop Med Hyg. 2009;81(2):240–247. https://www.ncbi.nlm.nih.gov/pubmed/19635877 [PubMed] [Google Scholar]
  • 20.Ximenes RAA, Pereira LMB, Martelli CMT, Merchán-Hamann E, Stein AT, Figueiredo GM. Methodology of a nationwide cross-sectional survey of prevalence and epidemiological patterns of hepatitis A, B and C infection in Brazil. Cad Saúde Pública. 2010;26(9):1693–1704. doi: 10.1590/S0102-311X2010000900003. [DOI] [PubMed] [Google Scholar]
  • 21.Pereira LM, Martelli CM, Moreira RC, Merchan-Hamman E, Stein AT, Cardoso MR. Prevalence and risk factors of Hepatitis C virus infection in. Brazil, 2005 through. 2009:a–a. doi: 10.1186/1471-2334-13-60. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Khan N, Khan N, Hussain J, Ullah H, Khan H. Frequency of hepatitis C in type 2 diabetic patients. Gomal J Med Sci. 2014;12(2):81–83. http://www.gjms.com.pk/ojs24/index.php/gjms/article/view/1033/633 [Google Scholar]
  • 23.Korkmaz H, Kesli R, Pamuk BO, Ipekci SH, Terzi Y, Kebapcilar L. Assessment of evidence for positive association and seroprevalence of hepatitis B and C in diabetic patients in a developing country. J Investig Med. 2015;63:251–257. doi: 10.1097/JIM.0000000000000126. [DOI] [PubMed] [Google Scholar]
  • 24.Esparsa-Martín N, Hernández-Betancor A, Suria-González S, Batista-García F, Braillard-Pocard P, Sánchez-Santana AY. Serology for hepatitis B and C, HIV and syphilis in the initial evaluation of diabetes patients referred for an external nephrology consultation. Nefrologia. 2013;33(1):124–127. doi: 10.3265/Nefrologia.pre2012.Jul.11331. [DOI] [PubMed] [Google Scholar]
  • 25.Ozyilkan E, Erbas T, Simsek H, Telatar F, Kayhan B, Telatar H. Increased prevalence of hepatitis C vírus antibodies in patients with diabetes mellitus. J Intern Med. 1994;235(3):283–284. doi: 10.1111/j.1365-2796.1994.tb01075. [DOI] [PubMed] [Google Scholar]
  • 26.Halota W, Muszynska M, Pawlowska M. Hepatitis B virus serologic markers and anti-hepatitis B vaccination in patients with diabetes. Med Sci Monit. 2002;8(7):516–519. https://www.ncbi.nlm.nih.gov/pubmed/12118201 [PubMed] [Google Scholar]
  • 27.Sangiorgio L, Attardo T, Gangemi R, Rubino C, Barone M, Lunetta M. Increased frequency of HCV and HBV infection in type 2 diabetic patients. Diabetes Res Clin Pract. 2000;48(2):147–151. doi: 10.1016/s0168-8227(99)00135-7. https://www.ncbi.nlm.nih.gov/pubmed/10802152 [DOI] [PubMed] [Google Scholar]
  • 28.Gulcan A, Gulcan E, Toker A, Bulut I, Akcan Y. Evaluation of risk factors and seroprevalence of hepatitis B and C in diabetic patients in Kutahya, Turkey. J Investig Med. 2008;56(6):858–863. doi: 10.2310/JIM.0b013e3181788d28. [DOI] [PubMed] [Google Scholar]
  • 29.Soverini V, Persico M, Bugianesi E, Forlani G, Salamone F, Masarone M. HBV and HCV infection in type 2 diabetes mellitus a survey in three diabetes units in different Italian areas. Acta Diabetol. 2011;48(4):337–343. doi: 10.1007/s00592-011-0293-x. [DOI] [PubMed] [Google Scholar]
  • 30.Onyekwere CA, Ogbera AO, Dada AO, Adeleye OO, Dosunmu AO, Akinbami AA. Hepatitis C Virus (HCV) Prevalence in Special Populations and Associated Risk Factors A Report From a Tertiary Hospital. Hepat Mon. 2016;16(5):e35532. doi: 10.5812/hepatmon.35532. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Pacher BM, Costa MRB, Nascimento MMP, Moura MC, Passos ADC. Hepatitis B and C in a Brazilian deaf community. Rev Soc Bras Med Trop. 2015;48(5):603–606. doi: 10.1590/0037-8682-0058-2015. [DOI] [PubMed] [Google Scholar]
  • 32.Villar LM, Ó KM, Scalioni LP, Cruz HM, Portilho MM, Mendonça AC. Prevalence of hepatitis B and C virus infections among military personnel. Braz J Infect Dis. 2015;19(3):285–290. doi: 10.1016/j.bjid.2015.02.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Mol MP, Gonçalves JP, Silva EA, Scarponi CF, Greco DB, Cairncross S. Seroprevalence of hepatitis B and C among domestic and healthcare waste handlers in Belo Horizonte, Brazil. Waste Manag Res. 2016;34(9):875–883. doi: 10.1177/0734242X16649686. [DOI] [PubMed] [Google Scholar]
  • 34.Martins T, Machado DF, Schuelter-Trevisol F, Trevisol DJ, Vieira e Silva RA, Narciso-Schiavon JL, et al. Prevalence and factors associated with HCV infection among elderly individuals in a southern Brazilian city. Rev Soc Bras Med Trop. 2013;46(3):281–287. doi: 10.1590/0037-8682-0026-2013. [DOI] [PubMed] [Google Scholar]
  • 35.Rudoni S, Petit JM, Bour JB, Aho LS, Castaneda A, Vaillant G, et al. HCV infection and diabetes mellitus: influence of the use of finger stick devices on nosocomial transmission. Diabetes Metab. 1999;25(6):502–505. https://www.ncbi.nlm.nih.gov/pubmed/10633875 [PubMed] [Google Scholar]
  • 36.White DL, Ratziu V, El-Serag HB. Hepatitis C infection and risk of diabetes a systematic review and meta-analysis. J Hepatol. 2008;49(5):831–844. doi: 10.1016/j.jhep.2008.08.006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Naing C, Mak JW, Ahmed SI, Maung M. Relationship between hepatitis C virus infection and type 2 diabetes mellitus meta-analysis. World J Gastroenterol. 2012;18(14):1642–1651. doi: 10.3748/wjg.v18.i14.1642. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Knobler H, Malnick S. Hepatitis C and insulin action An intimate relationship. Wld J Hepatol. 2016;8(2):131–138. doi: 10.4254/wjh.v8.i2.131. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Burman BE, Bacchetti P, Ayala CE, Gelman N, Melgar J, Khalili M. Liver inflammation is a risk factor for prediabetes in at-risk latinos with and without hepatitis C infection. Liver Int. 2015;35(1):101–107. doi: 10.1111/liv.12676. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Revista Latino-Americana de Enfermagem are provided here courtesy of Escola de Enfermagem de Ribeirao Preto, Universidade de Sao Paulo

RESOURCES